SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow,

Vaxcyte is a clinical-stage vaccine innovation company based in San Carlos, California with the unique ability to rapidly engineer, optimize and manufacture superior, high-fidelity vaccines at scale.

Streptococcus pneumoniae, Group A Strep and Shigella – for which we are advancing vaccine candidates – are among the World Health Organization’s top antibiotic-resistant pathogens requiring urgent solutions. At Vaxcyte, we are focusing our efforts on developing broadly protective vaccines to address the following:

Vaxcyte’s cell-free protein synthesis platform provides the opportunity to develop groundbreaking vaccines with unmatched efficiency.

Feb 25, 2025 · Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

Feb 25, 2025 · About Vaxcyte Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

When we began this mission over a decade ago, we set out to make a meaningful difference in protecting humankind from the consequences of bacterial diseases like invasive pneumococcal disease. We determined early on that developing a more broadly protective PCV was the highest and best use of our technology, and we believe our unique platform has enabled us to develop one of the most complex ...

Mar 4, 2024 · The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a Phase 3-ready 24-valent, broad-spectrum, carrier-sparing PCV being developed for the prevention of IPD.

San Carlos, California / Non Clinical & Immunoassay Development / Full-time / Onsite

Jan 5, 2023 · Vaxcyte nominated a final vaccine candidate for VAX-PG, its novel therapeutic vaccine designed to treat periodontal disease, in the fourth quarter of 2022 and continues to progress the program.